These findings suggest that RGL1 and ARHGEF9 are essential for proliferation and stemness maintenance in H3K27-altered DMG tumor cells, highlighting RGL1 and ARHGEF9 as potential therapeutic targets for future DMG treatment. This evidence concerns the gene ARHGEF9 and neoplasm.